Table 3 List of detected positron emission tomography agents
Positron Emission Tomography Agent as Stated in ClinicalTrials.gov | Radionuclid | IUPAC name of the carrier or other relevant source | Number of trials |
|---|---|---|---|
Acetate | (11C)a | Acetate | 22 |
Choline | (11C)a | 2-Hydroxy-N,N,N-trimethylethan-1-aminium | 16 |
Choline | (18F)a | 2-Hydroxy-N,N,N-trimethylethan-1-aminium | 37 |
Choline | NOSa | 2-Hydroxy-N,N,N-trimethylethan-1-aminium | 7 |
Citrate | (68Ga) | 2-Hydroxypropane-1,2,3-tricarboxylic acid | 1 |
DFO-huJ591 | (89Zr) | Recombinant humanized monoclonal antibody J591 conjugated to chelator desferrioxamine B | 1 |
DFO-MSTP2109A | (89Zr) | Desferrioxamine - DFO-MSTP2109A is an antibody that works against STEAP1 - found on the surface of prostate cancer cells | 1 |
DHT | (18F)a | (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one | 3 |
DOTA-Bombesin | (68Ga) | 68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is [4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]-acetyl. | 1 |
DOTATET | (68Ga) | 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (also known as DOTA) | 1 |
FAZA | (18F) | Nitroimidazole nucleoside analogue 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole (FAZA) | 2 |
FDG | (18F)a | 2-Deoxy-2-[18F]fluoroglucose | 15 |
FLT | (18F) | 1-[(2R,4S,5R)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione | 1 |
Fluciclovine | (18F) | Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid | 13 |
Fluciclovine | (NOS) | Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid | 1 |
Fluorocholine | (18F) | Fluoromethyl-(2-hydroxyethyl)-dimethylazanium;chloride | 1 |
FMAU | (18F) | 2′-deoxy-2′-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (fluorine F 18 d-FMAU [18F-FMAU]), | 3 |
MeAIB | (NOS)a | 2-methyl-2-(methylamino)propanoic acid | 1 |
Methionine | (11C)a | (2S)-2-amino-4-methylsulfanylbutanoic acid | 3 |
MISO | (18F) | 1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol | 1 |
NaF | (18F)a | Sodium;fluoride | 20 |
NODAGA-MJ9 | (Ga-68)a | 1,4,7-triazacyclononane,1-glutaric acid-4,7 acetic acid (NODAGA) | 1 |
NOTA-BBN-RGD | (68Ga) | 1,4,7-triazacyclononanetriacetic acid (NOTA), Arg-Gly-Asp (RGD) and bombesin (BBN) | 1 |
P15–041 | (68Ga) | Unknown | 1 |
PACAP | (64Cu) | Pituitary adenylate cyclase-activating peptide | 2 |
Peripheral Benzodiazepine Receptor-28 | (11C) | Peripheral Benzodiazepine Receptor-28 | 1 |
PSMA DCFPyL | (18F)a | N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine ([18F]DCFBC) | 21 |
PSMA | (68Ga) | Glutamate carboxypeptidase II, also known as N-acetyl-L-aspartyl-L-glutamate peptidase I | 15 |
PSMA | (89Zr) | Glutamate carboxypeptidase II, also known as N-acetyl-L-aspartyl-L-glutamate peptidase I | 2 |
PSMA CTT 1057 | (NOS) | Cancer Targeted Technology (CTT), a privately held Seattle-based biotechnology firm that will develop the agent, CTT1057. CTT1057 is a small molecule that homes in and binds irreversibly to prostate specific membrane antigen (PSMA) | 1 |
PSMA DCFBC | (18F) | (N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-F-fluorobenzyl-L-cysteine) (F-DCFBC) | 4 |
PSMA Df-IAB2M | (89Zr) | Zr-89-desferrioxamine-IAB2M | 1 |
RM2 | (68Ga) | 68Ga-RM2 stands for Galium-68 labeled DOTA-4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 | 3 |
Sodium Fluoride | (18F) | Sodium Fluoride | 1 |
uPAR NOTA | (68Ga) | Urokinase Plasminogen Activator Receptor | 1 |